Abstract
According to the Lupus Foundation of America, systemic lupus erythematosus (SLE) affects more than 1.5 million Americans. Common SLE treatments, including hydroxychloroquine, can cause severe side effects with long-term usage. Because of this, new treatments are needed. The SLE inflammatory response is characterized by the formation of autoantibodies against dsDNA. Nucleic acid autoantibodies can lead to the formation of immune complexes (ICs), which accumulate in the kidney and result in lupus nephritis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
